

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

FILE 'HOME' ENTERED AT 17:10:18 ON 30 SEP 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:10:24 ON 30 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2003 HIGHEST RN 594810-89-6

DICTIONARY FILE UPDATES: 28 SEP 2003 HIGHEST RN 594810-89-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STN Note 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s staurosporine

L1 118 STAUROSPORINE

=> s l1 and benzoyl

570646 BENZOYL

5 BENZOYLS

570646 BENZOYL

(BENZOYL OR BENZOYLS)

L2 21 L1 AND BENZOYL

=> d 1-21

L2 ANSWER 1 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN

RN 174567-14-7 REGISTRY

CN Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N-Benzoyl-N'-methylstaurosporine


FS STEREOSEARCH

MF C36 H32 N4 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174567-11-4 REGISTRY
CN Propanamide, N-(2-benzoyl-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-2-[(tetrahydro-2H-pyran-2-yl)oxy]-, stereoisomer (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N'-Benzoyl-N-[2-[(tetrahydro-2H-pyran-2-yl)oxy]propionyl]staurosporine
FS STEREOSEARCH
MF C43 H42 N4 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174567-10-3 REGISTRY
CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-g:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2-benzoyl-11-(ethylmethylamino)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 6-Benzoyl-N-ethylstaurosporine
FS STEREOSEARCH
MF C37 H34 N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174567-08-9 REGISTRY
CN Glycine, N-(2-benzoyl-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N'-Benzoyl-N-(carboxymethyl)staurosporine
MF C37 H32 N4 O6
CI COM
SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 5 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 174567-07-8 REGISTRY
 CN Glycine, N-(2-benzoyl-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, 1,1-dimethylethyl ester, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N'-Benzoyl-N-[(tert-butoxycarbonyl)methyl]staurosporine
 FS STEREOSEARCH
 MF C41 H40 N4 O6
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 174567-06-7 REGISTRY
 CN Benzamide, N-(2-benzoyl-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N,N'-Dibenzoylstaurosporine
 FS STEREOSEARCH
 MF C42 H34 N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174567-05-6 REGISTRY
CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2-benzoyl-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN N'-Benzoylstauroporine
FS STEREOSEARCH
MF C35 H30 N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174567-04-5 REGISTRY
CN Carbamic acid, (2-benzoyl-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)methyl-, 1,1-dimethylethyl ester, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N'-Benzoyl-N-(tert-butoxycarbonyl)staurosporine
FS STEREOSEARCH
MF C40 H38 N4 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174567-00-1 REGISTRY
CN Benzamide, N-[2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1,3-dioxo-2-(2-pyridinylmethyl)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-Benzoyl-7-oxo-N'-(2-pyridylmethyl)staurosporine
FS STEREOSEARCH
MF C41 H33 N5 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174566-99-5 REGISTRY
CN Benzamide, N-[2-[2-(diethylamino)ethyl]-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1,3-dioxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **N-Benzoyl-N'-[2-(diethylamino)ethyl]-7-oxostaurosporine**
FS STEREOSEARCH
MF C41 H41 N5 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174566-98-4 REGISTRY
CN Benzamide, N-[2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-2-(3-pyridinylcarbonyl)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **N-Benzoyl-N'-(3-pyridylcarbonyl)staurosporine**
FS STEREOSEARCH
MF C41 H33 N5 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 12 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174566-97-3 REGISTRY
CN Benzamide, N-[2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-2-(4-pyridinylcarbonyl)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **N-Benzoyl-N'-(4-pyridylcarbonyl)staurosporine**
FS STEREOSEARCH
MF C41 H33 N5 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 13 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174566-96-2 REGISTRY
CN Benzamide, N- [2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-2-(1H-pyrrol-2-ylcarbonyl)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **N-Benzoyl-N'-(1H-pyrrol-2-ylcarbonyl)staurosporine**


FS STEREOSEARCH


MF C40 H33 N5 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 14 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 174566-95-1 REGISTRY
CN Benzamide, N-[2-[2-(diethylamino)ethyl]-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **N-Benzoyl-N'-[2-(diethylamino)ethyl]staurosporine**


FS STEREOSEARCH

MF C41 H43 N5 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER


Absolute stereochemistry.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 15 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 165815-73-6 REGISTRY
CN Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-4-hydroxy-N-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-4-hydroxy-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]-
OTHER NAMES:
CN (4'-Hydroxybenzoyl)staurosporine
CN CGP 50723
MF C35 H30 N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 16 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
RN 165815-72-5 REGISTRY
CN Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-3-hydroxy-N-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-3-hydroxy-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]-
OTHER NAMES:

CN (3'-Hydroxybenzoyl)staurosporine
 CN CGP 50750
 MF C35 H30 N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 17 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 157318-74-6 REGISTRY
 CN Benzoic acid, 4-[[[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)methylamino]carbonyl]- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonine, benzoic acid deriv.
 CN Benzoic acid, 4-[[[(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)methylamino]carbonyl]-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]]-
 OTHER NAMES:
 CN N-(4-Carboxy benzoyl)staurosporine
 FS STEREOSEARCH
 MF C36 H30 N4 O6
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 18 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN

RN 154589-96-5 REGISTRY

CN Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1,3-dioxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonine, benzamide deriv.

CN Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1,3-dioxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]-

OTHER NAMES:

CN **N-Benzoyl-7-oxostaurosporine**


FS STEREOSEARCH

MF C35 H28 N4 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 19 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN

RN 120685-16-7 REGISTRY

CN Benzamide, 3-fluoro-N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonine, benzamide deriv.

CN Benzamide, 3-fluoro-N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]-

OTHER NAMES:

CN **N-(3-Fluorobenzoyl)-staurosporine**


FS STEREOSEARCH

MF C35 H29 F N4 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 20 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN

RN 120685-15-6 REGISTRY

CN Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-3-nitro- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonine, benzamide deriv.

CN Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-3-nitro-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]-

OTHER NAMES:

CN **N-(3-Nitrobenzoyl)staurosporine**


FS STEREOSEARCH

MF C35 H29 N5 O6

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 21 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN

RN 120685-11-2 REGISTRY

CN Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonine, benzamide deriv.

CN Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]-

OTHER NAMES:

CN **Benzoylstauropine**

CN CGP 41231

CN CGP 41251

CN Midostaurin

CN **N-Benzoylstauropine**

CN PKC 412


FS STEREOSEARCH

MF C35 H30 N4 O4

SR CA

LC STN Files: ADISINSIGHT, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, PHAR, PROMT, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

106 REFERENCES IN FILE CA (1907 TO DATE)
107 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus uspatful japio medline biosis embase
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
45.32	45.53

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:12:32 ON 30 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:12:32 ON 30 SEP 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 17:12:32 ON 30 SEP 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 17:12:32 ON 30 SEP 2003

FILE 'BIOSIS' ENTERED AT 17:12:32 ON 30 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 17:12:32 ON 30 SEP 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

=> s benzoylstauroporine or n-benoylstauroporine or 120685-11-2/rn

'RN' IS NOT A VALID FIELD CODE

'RN' IS NOT A VALID FIELD CODE

'RN' IS NOT A VALID FIELD CODE

'RN' IS NOT A VALID FIELD CODE

L3 413 BENZOYLSTAUROSPORINE OR N-BENOYLSTAUROSPORINE OR 120685-11-2/RN

=> s surfactant or polyoxyethylene or polyglycerol or polyol or copolymer or castor oil or polysorbate

L4 1385978 SURFACTANT OR POLYOXYETHYLENE OR POLYGLYCEROL OR POLYOL OR COPOLYMER OR CASTOR OIL OR POLYSORBATE

=> s l3 and l4

L5 40 L3 AND L4

=> dup rem 15
PROCESSING COMPLETED FOR L5
L6 40 DUP REM L5 (0 DUPLICATES REMOVED)

=> focus
PROCESSING COMPLETED FOR L6
L7 40 FOCUS L6 1-

=> d ibib abs 1-40

L7 ANSWER 1 OF 40 USPATFULL on STN
ACCESSION NUMBER: 2002:119885 USPATFULL
TITLE: Spontaneously dispersible N-benzoyl staurosporine compositions
INVENTOR(S): Matthews, Graham Paul, Horsham, UNITED KINGDOM
Haeberlin, Barbara, Munchenstein, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061873	A1	20020523
APPLICATION INFO.:	US 2001-930335	A1	20010815 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-EP1196, filed on 14 Feb 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-3547	19990216
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	849	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:754189 CAPLUS
DOCUMENT NUMBER: 137:268463
TITLE: Pharmaceutical compositions containing **surfactants** and polymers
INVENTOR(S): Ebner, Andreas; Galli, Bruno
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076432	A2	20021003	WO 2002-EP3387	20020326

WO 2002076432 A3 20021212

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU,
LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG,
SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, TR

DE 10117049 A1 20021017 DE 2001-10117049 20010405

PRIORITY APPLN. INFO.: DE 2001-10114869 A 20010326

DE 2001-10117049 A 20010405

AB A Solid compn. comprising (a) an anionic **surfactant** in combination with a water-sol. and basic polymer, or (b) a cationic **surfactant** in combination with a water-sol. and acidic polymer, and (c) at least 1 poorly water-sol. drug, and solid or liq. dosage forms, esp. tablets, coated tablets, capsules or suppositories or aq. solns. comprising the solid compn. The **surfactant**/polymer system is sol. in water and solubilizes the active ingredient so that good bioavailability with therapeutical quantities may be attained. Aq. solns. are suitable for nasal, parenteral or ophthalmic treatments. PVP-K30 (10 mg/mL), 10 mg/mL sodium dodecyl sulfate and an excess of PKC-412 are added at 25.degree. to water or pH 6.8 phosphate buffer. The mixt. is stirred for 24 h, whereby the polymer and the **surfactant** are completely dissolved, after which the mixt. is filtered. A clear soln. is obtained which contains 4.1 mg/mL of PKC-412. The soln. also remains unchanged after storage for 1 yr.

L7 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:592531 CAPLUS

DOCUMENT NUMBER: 133:183006

TITLE: Spontaneously dispersible N-
benzoylstaurosporine compositions

INVENTOR(S): Matthews, Graham Paul; Haberlin, Barbara

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen
Verwaltungsgesellschaft m.b.H.

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048571	A1	20000824	WO 2000-EP1196	20000214

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 2000008228	A	20011030	BR 2000-8228	20000214
---------------	---	----------	--------------	----------

EP 1152750	A1	20011114	EP 2000-909165	20000214
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2002537242	T2	20021105	JP 2000-599363	20000214
---------------	----	----------	----------------	----------

NO 2001003964	A	20011015	NO 2001-3964	20010815
---------------	---	----------	--------------	----------

US 2002061873	A1	20020523	US 2001-930335	20010815
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: GB 1999-3547 A 19990216

WO 2000-EP1196 W 20000214

AB Spontaneously dispersible N-**benzoylstaurosporine** compns. are described, for oral administration, having high bioavailability levels and reduced variability of bioavailability levels of N-**benzoylstaurosporine**, as well as their prepn. and use in treatment. Thus, a formulation contained Cremophor RH-40 42.750, PEG-400 25.65, EtOH 9.500, corn oil glycerides 17.005, tocopherol 0.095, and N-**benzoylstaurosporine** 5.000%.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:672544 CAPLUS
DOCUMENT NUMBER: 125:309030
TITLE: Nanosuspensions of N-**benzoylstaurosporine**
for intravenous application
INVENTOR(S): Weder, Hans Georg; Van Hoogevest, Peter
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733358	A2	19960925	EP 1996-810150	19960312
EP 733358	A3	19980520		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9648094	A1	19961003	AU 1996-48094	19960315
AU 9648095	A1	19961003	AU 1996-48095	19960315
CA 2172110	AA	19960922	CA 1996-2172110	19960319
CA 2172111	AA	19960922	CA 1996-2172111	19960319
JP 08268915	A2	19961015	JP 1996-63092	19960319
JP 08268893	A2	19961015	JP 1996-63194	19960319
NO 9601136	A	19960923	NO 1996-1136	19960320
NO 9601137	A	19960923	NO 1996-1137	19960320
ZA 9602248	A	19960923	ZA 1996-2248	19960320
ZA 9602249	A	19960923	ZA 1996-2249	19960320
US 5726164	A	19980310	US 1996-619068	19960320
PRIORITY APPLN. INFO.:			CH 1995-804	19950321

AB The title poorly water-sol. staurosporine deriv. (I), a protein kinase C inhibitor and antitumor agent, is solubilized for i.v. administration by dispersion with a **polyoxyethylene**-polyoxypropylene block **copolymer**, soybean lecithin or other phospholipid, EtOH, and H₂O. The resulting nanosuspension (particle size 5-20 nm) shows excellent homogeneity and storage stability. Thus, an aq. infusion soln. contained glucose 5, I 0.12, Lutrol F68 0.60, soybean lecithin 0.12, glycerin 1.80, 70% sorbitol soln. 0.88, and 96% EtOH 2.10%.

L7 ANSWER 5 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:672543 CAPLUS
DOCUMENT NUMBER: 125:309029
TITLE: Pharmaceutical base for the formulation of
nanosuspensions
INVENTOR(S): Weder, Hans Georg; Van Hoogevest, Peter
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.; Vesifact Ag
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733372	A2	19960925	EP 1996-810151	19960312
EP 733372	A3	19980520		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9648094	A1	19961003	AU 1996-48094	19960315
AU 9648095	A1	19961003	AU 1996-48095	19960315
CA 2172110	AA	19960922	CA 1996-2172110	19960319
CA 2172111	AA	19960922	CA 1996-2172111	19960319
JP 08268915	A2	19961015	JP 1996-63092	19960319
JP 08268893	A2	19961015	JP 1996-63194	19960319
NO 9601136	A	19960923	NO 1996-1136	19960320
NO 9601137	A	19960923	NO 1996-1137	19960320
ZA 9602248	A	19960923	ZA 1996-2248	19960320
ZA 9602249	A	19960923	ZA 1996-2249	19960320
US 5726164	A	19980310	US 1996-619068	19960320

PRIORITY APPLN. INFO.:

CH 1995-804

19950321

AB A base for formulation of pharmaceutical nanosuspensions of an active agent (e.g. N-**benzoylstaurosporine**, a poorly water-sol. protein kinase C inhibitor and antitumor agent) contains a **polyoxyethylene**-polyoxypropylene block **copolymer**, soybean lecithin or other phospholipid, EtOH, and H₂O. The resulting nanosuspension (particle size 5-20 nm) shows excellent homogeneity and storage stability. Thus, an aq. infusion soln. contained glucose 5, N-**benzoylstaurosporine** 0.12, Lutrol F68 0.60, soybean lecithin 0.12, glycerin 1.80, 70% sorbitol soln. 0.88, and 96% EtOH 2.10%.

L7 ANSWER 6 OF 40 USPATFULL on STN

ACCESSION NUMBER: 1998:25218 USPATFULL

TITLE: Nanosuspensions for intravenous administration

INVENTOR(S): Weder, Hans Georg, Ruschlikon, Switzerland

van Hoogevest, Peter, Riehen, Switzerland

PATENT ASSIGNEE(S): Novartis Corporation, Summit, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5726164		19980310
APPLICATION INFO.:	US 1996-619068		19960320 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1995-804	19950321
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ivy, C. Warren	
ASSISTANT EXAMINER:	Mach, D. Margaret M.	
LEGAL REPRESENTATIVE:	Mathias, Marla J., Ferraro, Gregory D.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	576	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical composition for the intravenous administration of the sparingly soluble staurosporin derivative N-benzoyl-staurosporin. The composition comprises the following preferred components:

- the therapeutic agent N-benzoyl-staurosporin;
- a **polyoxyethylene/polyoxypropylene block copolymer**;
- ethanol and water as carrier liquids; and

d) purified lecithin from soybeans and

e) as water-soluble excipients glycerol and sorbitol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:105883 USPATFULL

TITLE: Encapsulation of plasmid DNA (lipogenes.TM.) and
therapeutic agents with nuclear localization
signal/fusogenic peptide conjugates into targeted
liposome complexes

INVENTOR(S): Boulikas, Teni, Mountain View, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003072794	A1	20030417
APPLICATION INFO.:	US 2001-876904	A1	20010608 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-210925P	20000609 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Antoinette F. Konski, Baker & McKenzie, 660 Hansen Way, Palo Alto, CA, 94304	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	4201	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of encapsulated the plasmids, oligonucleotides or negatively-charged drugs with HSV-tk plus encapsulated ganciclovir.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 40 USPATFULL on STN

ACCESSION NUMBER: 97:73605 USPATFULL

TITLE: Intravenous solutions for a derivative of staurosporine

INVENTOR(S): Weder, Hans Georg, Ruschlikon, Switzerland

Isele, Ute, Ihringen, Germany, Federal Republic of

PATENT ASSIGNEE(S): CIBA GEIGY Corporation, Tarrytown, NY, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658898		19970819
APPLICATION INFO.:	US 1995-553126		19951107 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1994-3375	19941109
	CH 1995-595	19950302
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Mathias, Marla J., Ferraro, Gregory D.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	557	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a novel advantageous dosage form for sparingly soluble staurosporin derivatives, especially N-benzoyl-staurosporin. The dosage form is administrable intravenously in the form of a nanoemulsion and comprises as solubilisers a combination of phospholipids, triglycerides and partial fatty acid esters of **polyoxyethylene** sorbitan.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1996:357113 CAPLUS
 DOCUMENT NUMBER: 125:19059
 TITLE: Intravenous solutions containing staurosporine derivatives
 INVENTOR(S): Weder, Hans Georg; Isele, Ute
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 711556	A1	19960515	EP 1995-810686	19951101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9536616	A1	19960523	AU 1995-36616	19951102
AU 9536617	A1	19960523	AU 1995-36617	19951102
FI 9505311	A	19960510	FI 1995-5311	19951106
FI 9505312	A	19960510	FI 1995-5312	19951106
CA 2162341	AA	19960510	CA 1995-2162341	19951107
CA 2162342	AA	19960510	CA 1995-2162342	19951107
HU 74423	A2	19961230	HU 1995-3199	19951107
US 5658898	A	19970819	US 1995-553126	19951107
HU 78026	A2	19990528	HU 1995-3198	19951107
ZA 9509457	A	19960509	ZA 1995-9457	19951108
NO 9504485	A	19960510	NO 1995-4485	19951108
NO 9504486	A	19960510	NO 1995-4486	19951108
ZA 9509458	A	19960620	ZA 1995-9458	19951108
JP 08208486	A2	19960813	JP 1995-289508	19951108
JP 08208522	A2	19960813	JP 1995-289511	19951108
PRIORITY APPLN. INFO.:			CH 1994-3375	19941109
			CH 1995-595	19950302

OTHER SOURCE(S): MARPAT 125:19059

AB Poorly sol. staurosporine derivs., esp. N-benzoylstaurosporine, are formulated with a combination of phospholipids, triglycerides, and partial fatty esters of **polyoxyethylene**-sorbitan as solubilizers for i.v. administration. Staurosporine derivs. are useful as neoplasm and inflammation inhibitors, antibiotics, antiarteriosclerotics, etc. Thus, an oily mixt. of N-benzoylstaurosporine 9.0, Miglyol 812 100.0, and Tween 80 150.0 g was homogenized with an aq. liposome dispersion

contg. 50.0 g Lipoid S 100 and the nanoemulsion was sterilized by filtration for i.v. injection.

L7 ANSWER 10 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:357112 CAPLUS
DOCUMENT NUMBER: 125:19058
TITLE: Base for formulating intravenous pharmaceutical compositions containing staurosporine derivatives
INVENTOR(S): Weder, Hans Georg; Isele, Ute
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.; Vesifact Ag
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 711557	A1	19960515	EP 1995-810687	19951101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9536616	A1	19960523	AU 1995-36616	19951102
AU 9536617	A1	19960523	AU 1995-36617	19951102
FI 9505311	A	19960510	FI 1995-5311	19951106
FI 9505312	A	19960510	FI 1995-5312	19951106
CA 2162341	AA	19960510	CA 1995-2162341	19951107
CA 2162342	AA	19960510	CA 1995-2162342	19951107
HU 74423	A2	19961230	HU 1995-3199	19951107
US 5658898	A	19970819	US 1995-553126	19951107
HU 78026	A2	19990528	HU 1995-3198	19951107
ZA 9509457	A	19960509	ZA 1995-9457	19951108
NO 9504485	A	19960510	NO 1995-4485	19951108
NO 9504486	A	19960510	NO 1995-4486	19951108
ZA 9509458	A	19960620	ZA 1995-9458	19951108
JP 08208486	A2	19960813	JP 1995-289508	19951108
JP 08208522	A2	19960813	JP 1995-289511	19951108
PRIORITY APPLN. INFO.:			CH 1994-3375	19941109
			CH 1995-595	19950302

OTHER SOURCE(S): MARPAT 125:19058

AB Poorly sol. staurosporine derivs., esp. N-benzoylstauroporine, are formulated with a combination of phospholipids, triglycerides, and partial fatty esters of polyoxyethylene-sorbitan as solubilizers for i.v. administration. Staurosporine derivs. are useful as neoplasm and inflammation inhibitors, antibiotics, antiarteriosclerotics, etc. Thus, an oily mixt. of N-benzoylstauroporine 9.0, Miglyol 812 100.0, and Tween 80 150.0 g was homogenized with an aq. liposome dispersion contg. 50.0 g Lipoid S 100 and the nanoemulsion was sterilized by filtration for i.v. injection.

L7 ANSWER 11 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:93662 USPATFULL
TITLE: Fatty amine drug conjugates
INVENTOR(S): Swindell, Charles S., Merion, PA, UNITED STATES
Fegley, Glenn J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003065023	A1	20030403
APPLICATION INFO.:	US 2002-108255	A1	20020325 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-278552P	20010323 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Esq., Chantal Morgan D'Apuzzo, Wolf,
Greenfield & Sacks, P.C., 600 Atlantic Ave., Boston,
MA, 02210
NUMBER OF CLAIMS: 130
EXEMPLARY CLAIM: 1
LINE COUNT: 2761

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty amines and pharmaceutical
agents useful in treating cancer, viruses, psychiatric disorders.
Compositions, pharmaceutical preparations, and methods of preparations
of the fatty amine-pharmaceutical agent conjugates are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 40 USPATFULL on STN
ACCESSION NUMBER: 2002:315123 USPATFULL
TITLE: Fatty alcohol drug conjugates
INVENTOR(S): Swindell, Charles S., Merion, PA, UNITED STATES
Fegley, Glenn J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002177609	A1	20021128
APPLICATION INFO.:	US 2002-107537	A1	20020325 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-278457P	20010323 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Edward R. Gates, Esq., Chantal Morgan D'Apuzzo, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Ave, Boston, MA, 02210	
NUMBER OF CLAIMS:	136	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2864	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty alcohols and pharmaceutical
agents useful in treating cancer, viruses, psychiatric disorders.
Compositions, pharmaceutical preparations, and methods of preparation of
the fatty alcohols-pharmaceutical agent conjugates are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 40 USPATFULL on STN
ACCESSION NUMBER: 2003:85867 USPATFULL
TITLE: Oral delivery formulation
INVENTOR(S): Compton, Bruce Jon, Lexington, MA, UNITED STATES
Solari, Nancy E., West Newton, MA, UNITED STATES
Flangan, Margaret A., Stow, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003059471	A1	20030327
APPLICATION INFO.:	US 2001-997277	A1	20011129 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-55560, filed on 6 Apr 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69501P	19971215 (60)
	US 1998-73867P	19980204 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen J Gaudet, 68H Stiles Road, Salem, NH, 03079
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 2950
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Flakes containing drugs and methods for forming and using such flakes
are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:521462 CAPLUS
DOCUMENT NUMBER: 137:88442
TITLE: Incensole and furanogermacrene and compounds in
treatment for inhibiting neoplastic lesions and
microorganisms
INVENTOR(S): Shanahan-Pendergast, Elisabeth
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102
WO 2002053138	A3	20020919		
W:	AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: IE 2001-2 A 20010102

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrene, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacrene and their mixt. showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

L7 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:242143 CAPLUS
DOCUMENT NUMBER: 138:260470
TITLE: Ophthalmic depot formulations for periocular or subconjunctival administration
INVENTOR(S): Ahlheim, Markus; Ausborn, Michael; Bodmer, David; Schoch, Christian
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024420	A1	20030327	WO 2002-EP10314	20020913

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU,
 LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG,
 SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
 LU, MC, NL, PT, SE, SK, TR

PRIORITY APPLN. INFO.: GB 2001-22318 A 20010914

OTHER SOURCE(S): MARPAT 138:260470

AB The present invention relates to ophthalmic depot formulations comprising an active agent, e.g., staurosporine or phthalazine derivs., embedded in a pharmacol. acceptable biocompatible polymer or a lipid encapsulating agent, for periocular or subconjunctival administration. For example, microparticles were prepd. contg. a staurosporine deriv. 0.10 g, polymer Glu-PLG 0.90 g, methylene chloride 2.5 mL, 1.5% aq. polyvinyl chloride 500 mL, and 0.5% aq. polyvinyl chloride 3 L.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2002:17328 USPATFULL

TITLE: Dha-pharmaceutical agent conjugates of taxanes

INVENTOR(S): Shashoua, Victor, Brookline, MA, UNITED STATES

Swindell, Charles, Merion, PA, UNITED STATES

Webb, Nigel, Bryn Mawr, PA, UNITED STATES

Bradley, Matthews, Layton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010208	A1	20020124
	US 6602902	B2	20030805
APPLICATION INFO.:	US 2001-846838	A1	20010501 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US 5795909		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2437		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2001:121065 USPATFULL

TITLE: Attaching agents to tissue with transglutaminase and a transglutaminase substrate

INVENTOR(S): Green, Howard, 82 Williston St., Brookline, MA, United States 02146

Corey, George D., 65 Harding St., Newton, MA, United States 02165

Compton, Bruce J., 30 Cottage St., Lexington, MA, United States 02173

Dijan, Philippe, 170, rue de la Convention, 75015

Paris, France

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6267957	B1	20010731
APPLICATION INFO.:	US 1999-234358		19990120 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-71908P	19980120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Naff, David M.	
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1730	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, products and kits are provided for attaching agents to tissue with a linking molecule in the presence of transglutaminase. The linking molecule and/or agent is a substrate of transglutaminase. The agent can be a nonprotein or an enzyme such as cholinesterase or phosphodiesterase. The transglutaminase may be exogenously added or be endogenous in tissue. In specific embodiments, the linking molecule contains at least two contiguous linked glutamines or at least three contiguous linked lysines. A conjugate of the agent and the linking molecule may be applied to tissue, and in the presence of transglutaminase covalently bonded to the tissue via the linking molecule. A complementary linking molecule rich in lysines may be first attached to the tissue in the presence of transglutaminase, and then covalently bonded to a glutamine-containing linking molecule of the conjugate in the presence of transglutaminase. In another embodiment, a linking molecule containing multiple glutamines is covalently bonded to tissue in the presence of transglutaminase, and an agent containing multiple lysines is covalently bonded to the linking molecule in the presence of transglutaminase. Alternatively, the linking molecule contains multiple lysines and the agent contains multiple glutamines. Two tissues can be sealed together by holding the tissues in contact with each other in the presence of transglutaminase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2001:90260 USPATFULL
TITLE: Fatty acid-pharmaceutical agent conjugates
INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001002404	A1	20010531
	US 6576636	B2	20030610
APPLICATION INFO.:	US 2000-730450	A1	20001205 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 14 Drawing Page(s)

LINE COUNT: 2511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 40 USPATFULL on STN

ACCESSION NUMBER: 1998:98932 USPATFULL

TITLE: DHA-pharmaceutical agent conjugates of taxanes

INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States

Swindell, Charles S., Merion, PA, United States

Webb, Nigel L., Bryn Mawr, PA, United States

Bradley, Matthews O., Laytonsville, MD, United States

PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795909		19980818
APPLICATION INFO.:	US 1996-651312		19960522 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2451		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2000:80885 USPATFULL

TITLE: Taxanes

INVENTOR(S): Swindell, Charles S., Merion, PA, United States

Shashoua, Victor E., Brookline, MA, United States

Bradley, Matthews O., Laytonsville, MD, United States

Webb, Nigel L., Bryn Mawr, PA, United States

PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6080877		20000627
APPLICATION INFO.:	US 1997-868476		19970603 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-651429, filed on 22 May 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Trinh, Ba K.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	1034		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides taxanes that are conjugates of cis-docosahexaenoic acid and taxotere. The conjugates are useful in treating cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 40 USPATFULL on STN

ACCESSION NUMBER: 1999:75671 USPATFULL
TITLE: Taxane compounds and compositions
INVENTOR(S): Bradley, Matthews O., Laytonville, MD, United States
Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5919815		19990706
APPLICATION INFO.:	US 1996-653951		19960522 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Reamer, James H.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1,4		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	940		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides taxanes that are conjugates of cis-docosahexaenoic acid and paclitaxel. The conjugates are useful in treating cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:173899 USPATFULL
TITLE: Methods of using pharmaceutical compositions comprising troponin subunits and homologs thereof before, during, or after surgical resection or radiologic ablation of a solid tumor
INVENTOR(S): Lanser, Marc E., Dover, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119747	A1	20030626
APPLICATION INFO.:	US 2002-286134	A1	20021101 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-335133P	20011101 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NIXON PEABODY LLP, 101 FEDERAL ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	2125	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for using pharmaceutical compositions containing troponin subunits C, I, or T in therapeutically effective amounts to inhibit angiogenesis before, during, or after surgical resection or radiologic ablation of a solid tumor. The invention also relates to using pharmaceutical compositions containing

homologs of troponin subunits C, I, or T and homologs of their fragments in therapeutically effective amounts to inhibit angiogenesis before, during, or after surgical resection or radiologic ablation of a solid tumor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:226301 USPATFULL

TITLE: Anti-tumor agents

INVENTOR(S): Wallner, Barbara, Cohasset, MA, UNITED STATES

Miller, Glenn, Merrimac, MA, UNITED STATES

PATENT ASSIGNEE(S): Point Therapeutics, Inc., Boston, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158114	A1	20030821
APPLICATION INFO.:	US 2003-384121	A1	20030307 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-578363, filed on 25 May 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-135861P	19990525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2082	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:173964 USPATFULL

TITLE: Method for decreasing capillary permeability in the retina

INVENTOR(S): Brazzell, Romulus Kimbro, Alpharetta, GA, UNITED STATES
Campochiaro, Peter Anthony, Baltimore, MD, UNITED STATES

Green, Kenneth, Alpharetta, GA, UNITED STATES

Kane, Frances Elizabeth, Cumming, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119812	A1	20030626
APPLICATION INFO.:	US 2002-288767	A1	20021104 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-337691P	20011108 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ,	

07936-1080

NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods for decreasing or attenuating an increase in capillary permeability in a subject in need of treatment by administering a composition comprising an amount of a staurosporine derivative or salt thereof to a subject suffering from excessive or pathological capillary permeability in the retina effective to decrease the permeability of the retinal capillaries of the subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 25 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:153332 USPATFULL
TITLE: Methods and compositions for inhibiting GRB7
INVENTOR(S): Pero, Stephanie C., Essex Junction, VT, UNITED STATES
Krag, David N., Shelburne, VT, UNITED STATES
Oligino, Lyn, South Burlington, VT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003105000	A1	20030605
APPLICATION INFO.:	US 2001-13815	A1	20011105 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245755P	20001103 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	93	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	4785	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods and compositions for treating subjects using Grb7 antagonists. Specifically disclosed are Grb7 antagonists that bind selectively to Grb7 and interfere with the ability of Grb7 to bind to its native ligands. These compositions are useful in the prevention and treatment of disorders characterized by abnormal interaction of Grb7 with its native ligands (e.g., ErbB2).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 26 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2002:236030 USPATFULL
TITLE: Compositions and methods for the treatment of cancer
INVENTOR(S): Hwu, Wen-Jen, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002128228	A1	20020912
APPLICATION INFO.:	US 2001-1281	A1	20011130 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-250130P	20001201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW	

YORK, NY, 100362711

NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 2149

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 27 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2002:61254 USPATFULL
TITLE: Compositions and methods for the treatment of cancer
INVENTOR(S): Zeldis, Jerome B., Princeton, NJ, UNITED STATES
Zeitlin, Andrew L., Basking Ridge, NJ, UNITED STATES
Barer, Sol, Westfield, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002035090	A1	20020321
APPLICATION INFO.:	US 2001-853617	A1	20010514 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-204143P	20000515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1973	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 28 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:71970 USPATFULL

TITLE: Sugar derivatives of hydromorphone, dihydromorphone and dihydroisomorphine, compositions thereof and uses for treating or preventing pain

INVENTOR(S): Gao, Feng, Stamford, CT, UNITED STATES
Miotto, Jahanara, Carmel, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003050257	A1	20030313
APPLICATION INFO.:	US 2002-199526	A1	20020722 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-307845P	20010727 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006	
NUMBER OF CLAIMS:	56	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1498	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Glucoside and glucuronide derivatives of hydromorphone, dihydromorphone, and dihydroisomorphine and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising a glucoside or glucuronide derivative of hydromorphone, dihydromorphone, or dihydroisomorphine or a pharmaceutically acceptable salt thereof, and methods for treating or preventing pain in a patient comprising administering to a patient in need thereof a glucoside or glucuronide derivative of hydromorphone, dihydromorphone, or dihydroisomorphine or a pharmaceutically acceptable salt thereof are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 29 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:220260 USPATFULL

TITLE: Method for treating ocular neovascular diseases

INVENTOR(S): Brazzell, Romulus Kimbro, Alpharetta, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153551	A1	20030814
APPLICATION INFO.:	US 2003-364607	A1	20030211 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-356792P	20020213 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	456	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method for causing regression of ocular neovascularization in a subject by administering an effective amount of a staurosporine derivative to the subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 30 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:100138 USPATFULL
TITLE: Nociceptin analogs
INVENTOR(S): Sun, Qun, Belle Mead, NJ, UNITED STATES
Goehring, R. Richard, Pipersville, PA, UNITED STATES
Kyle, Donald, Newtown, PA, UNITED STATES
Chen, Zhengming, Belle Mead, NJ, UNITED STATES
Victory, Sam, Newtown, PA, UNITED STATES
Whitehead, John, Newtown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069249	A1	20030410
APPLICATION INFO.:	US 2002-126471	A1	20020418 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284666P	20010418 (60)
	US 2001-284667P	20010418 (60)
	US 2001-284668P	20010418 (60)
	US 2001-284669P	20010418 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018	
NUMBER OF CLAIMS:	124	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4475	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	A compound of the formula (I), (II), (III) or (IV)	##STR1##

wherein Z, A, B, C, R, R.sub.1, R.sub.2, Q, and n are as described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 31 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:89383 USPATFULL
TITLE: Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
INVENTOR(S): Roder, Hanno, Ratingen, GERMANY, FEDERAL REPUBLIC OF
Lowinger, Timothy B., Nishinomiya, JAPAN
Brittelli, David R., Branford, CT, United States
VanZandt, Michael C., Guilford, CT, United States
PATENT ASSIGNEE(S): Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6541468	B1	20030401
APPLICATION INFO.:	US 1999-382539		19990825 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-109131, filed on 2 Jul 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kifle, Bruck		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1462		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Novel indolocarbazole derivatives potentially useful for the treatment		

of dementias characterized by tau hyperphosphorylation [Alzheimer's disease (AD), frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotising panencephalitis (SSPE) as a late complication of viral infections in the CNS], and cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 32 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:79087 USPATFULL

TITLE: Inhibition of angiogenesis by nucleic acids

INVENTOR(S): Bratzler, Robert L., Concord, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055014	A1	20030320
APPLICATION INFO.:	US 2001-17995	A1	20011214 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255534P	20001214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Maria A. Trevisan, c/o Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	74	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	3268	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods and products for inhibiting angiogenesis. At least one antiangiogenic nucleic acid molecule is administered to a subject to prevent or treat unwanted angiogenesis. Non-nucleic acid antiangiogenic agents also can be administered.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 33 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2003:38187 USPATFULL

TITLE: Spiropyrazole compounds

INVENTOR(S): Goehring, R. Richard, Pipersville, PA, UNITED STATES

Lee, Gary, West Windsor, NJ, UNITED STATES

Gharagozloo, Parviz, Pennington, PA, UNITED STATES

Victory, Sam, Newtown, PA, UNITED STATES

Kyle, Donald, Newtown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027834	A1	20030206
APPLICATION INFO.:	US 2002-126506	A1	20020418 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284675P	20010418 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1524	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I): ##STR1##

wherein

Z, W, A, B, C, R.sub.1, R.sub.2, Q and n are as disclosed herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 34 OF 40 USPATFULL on STN
ACCESSION NUMBER: 2003:30960 USPATFULL
TITLE: Use of methylnaltrexone to treat immune suppression
INVENTOR(S): Moss, Jonathan, Chicago, IL, UNITED STATES
Yuan, Chun-Su, Chicago, IL, UNITED STATES
PATENT ASSIGNEE(S): University of Chicago, Chicago, IL (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022909	A1	20030130
APPLICATION INFO.:	US 2002-163482	A1	20020605 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-295571P	20010605 (60)
	US 2002-374454P	20020422 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Chantal Morgan D'Apuzzo, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Ave., Boston, MA, 02210	
NUMBER OF CLAIMS:	81	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1407	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating opioid-induced immune suppression with peripheral opioid antagonists are provided. In one embodiment, the method involves administering methylnaltrexone. Pharmaceutical compositions comprising an opioid, an opioid antagonist, and a pharmaceutical agent are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 35 OF 40 USPATFULL on STN
ACCESSION NUMBER: 2003:24198 USPATFULL
TITLE: Spiroindene and spiroindane compounds
INVENTOR(S): Goehring, R. Richard, Pipersville, PA, UNITED STATES
Vicotry, Sam, Newtown, PA, UNITED STATES
Kyle, Donald, Newtown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018041	A1	20030123
APPLICATION INFO.:	US 2002-126472	A1	20020418 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284670P	20010418 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Davidson, Davidson & Kappel, LLC, 485 Seventh Avenue, 14th Floor, New York, NY, 10018	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1737	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I): ##STR1##

wherein

Z, A, B, C, R.sub.1, R.sub.2, X.sub.1, X.sub.2, Q and n are as disclosed herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 36 OF 40 USPATFULL on STN
ACCESSION NUMBER: 2003:18117 USPATFULL
TITLE: Nociceptin analogs
INVENTOR(S): Goehring, R. Richard, Pipersville, PA, UNITED STATES
Chen, Zhengming, Belle Mead, NJ, UNITED STATES
Whitehead, John, Newtown, PA, UNITED STATES
Gharagozloo, Parviz, Pennington, NJ, UNITED STATES
Victory, Sam, Newtown, PA, UNITED STATES
Kyle, Donald, Newton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003013874	A1	20030116
APPLICATION INFO.:	US 2002-126507	A1	20020418 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284674P	20010418 (60)
	US 2001-284676P	20010418 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018	
NUMBER OF CLAIMS:	62	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2507	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the having the general formula (I) or general formula (II): ##STR1##

wherein

Z, A, B, C, R.sub.1, R.sub.2, Q, W, and n are as described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 37 OF 40 USPATFULL on STN
ACCESSION NUMBER: 2003:11182 USPATFULL
TITLE: Benzimidazolone compounds
INVENTOR(S): Goehring, R. Richard, Pipersville, PA, UNITED STATES
Chen, Zhengming, Belle Mead, NJ, UNITED STATES
Victory, Sam, Newtown, PA, UNITED STATES
Kyle, Donald, Newtown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003008886	A1	20030109
APPLICATION INFO.:	US 2002-126437	A1	20020418 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284665P	20010418 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	

LINE COUNT: 1637

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compounds of the formula (I): ##STR1##

wherein A, B, C, M.sub.1-M.sub.4, R, R.sub.1, R.sub.2 and n are as described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 38 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2002:343913 USPATFULL

TITLE: Methods and products for analyzing nucleic acids based on methylation status

INVENTOR(S): Shia, Michael A., Cambridge, MA, UNITED STATES
Wong, Gordon G., Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002197639	A1	20021226
APPLICATION INFO.:	US 2002-165914	A1	20020610 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-297147P	20010608 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	106	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2196	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods, products and systems for analyzing nucleic acid molecules based on their in vivo methylation status. The methods can be used to obtain sequence information about the nucleic acid molecules, to analyze differential gene expression associated with disorders, and to assess the efficacy of therapeutic treatments that affect methylation status.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 39 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2002:213436 USPATFULL

TITLE: Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation

INVENTOR(S): Rubinfeld, Joseph, Danville, CA, UNITED STATES
Chang, Lucy, San Mateo, CA, UNITED STATES
DiMartino, Jorge, San Carlos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002114809	A1	20020822
	US 6613753	B2	20030902
APPLICATION INFO.:	US 2001-790483	A1	20010221 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1466		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for treating diseases associated

with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent such as monoclonal antibody and interferon.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 40 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2000:4808 USPATFULL

TITLE: Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

INVENTOR(S): Roder, Hanno, Ratingen, Germany, Federal Republic of
Lowinger, Timothy B., Nishinomiya, Japan
Brittelli, David R., Branford, CT, United States
VanZandt, Michael C., Guilford, CT, United States

PATENT ASSIGNEE(S): Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013646		20000111
APPLICATION INFO.:	US 1998-109131		19980702 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Kifle, Bruck		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1457		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel indolocarbazole derivatives potentially useful for the treatment of dementias characterized by tau hyperphosphorylation [Alzheimer's disease (AD), frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) as a late complication of viral infections in the CNS], and cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 17 3 ibib abs re

L7 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:592531 CAPLUS

DOCUMENT NUMBER: 133:183006

TITLE: Spontaneously dispersible N-benzoylstauroporine compositions

INVENTOR(S): Matthews, Graham Paul; Haberland, Barbara

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048571	A1	20000824	WO 2000-EP1196	20000214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000008228	A	20011030	BR 2000-8228	20000214
EP 1152750	A1	20011114	EP 2000-909165	20000214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537242	T2	20021105	JP 2000-599363	20000214
NO 2001003964	A	20011015	NO 2001-3964	20010815
US 2002061873	A1	20020523	US 2001-930335	20010815
PRIORITY APPLN. INFO.:			GB 1999-3547	A 19990216
			WO 2000-EP1196	W 20000214


AB Spontaneously dispersible N-**benzoylstaurosporine** compns. are described, for oral administration, having high bioavailability levels and reduced variability of bioavailability levels of N-**benzoylstaurosporine**, as well as their prepn. and use in treatment. Thus, a formulation contained Cremophor RH-40 42.750, PEG-400 25.65, EtOH 9.500, corn oil glycerides 17.005, tocopherol 0.095, and N-**benzoylstaurosporine** 5.000%.

RE

- (1) Ciba-Geigy Ag; EP 0657164 A 1995 CAPLUS
- (2) Ciba-Geigy Ag; EP 0711556 A 1996 CAPLUS
- (3) Ciba-Geigy Ag; EP 0733358 A 1996 CAPLUS
- (4) Novartis Ag; WO 9833512 A 1998 CAPLUS
- (5) Sandoz-Patent-GmbH; DE 4418115 A 1994 CAPLUS

L2 ANSWER 21 OF 21 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 120685-11-2 REGISTRY
 CN Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonine, benzamide deriv.
 CN Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]-
 OTHER NAMES:
 CN **Benzoylstaurosporine**
 CN CGP 41231
 CN CGP 41251
 CN Midostaurin
 CN **N-Benzoylstaurosporine**
 CN PKC 412
 FS STEREOSEARCH
 MF C35 H30 N4 O4
 SR CA
 LC STN Files: ADISINSIGHT, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, PHAR, PROMT, TOXCENTER, USAN, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

106 REFERENCES IN FILE CA (1907 TO DATE)
 107 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1995:708711 CAPLUS
DN 123:93287
TI Pharmaceutical compositions containing staurosporine derivatives
IN Henry, Roy Lindsay Allen; Matthews, Graham Paul
PA Ciba-Geigy A.-G., Switz.
SO Eur. Pat. Appl., 6 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 657164	A1	19950614	EP 1994-308954	19941202
	EP 657164	B1	19991027		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5736542	A	19980407	US 1994-343404	19941122
	AT 185970	E	19991115	AT 1994-308954	19941202
	ES 2140512	T3	20000301	ES 1994-308954	19941202
	IL 111872	A1	19980208	IL 1994-111872	19941205
	AU 9480308	A1	19950622	AU 1994-80308	19941208
	AU 692801	B2	19980618		
	CA 2137764	AA	19950612	CA 1994-2137764	19941209
	ZA 9409824	A	19950713	ZA 1994-9824	19941209
	JP 07196512	A2	19950801	JP 1994-307534	19941212
PRAI	GB 1993-25395	A	19931211		
AB	An oral prepn. with an improved bioavailability, comprises a soln. or dispersion of a staurosporine active ingredient in a satd. polyalkylene glycol glyceride, such as <u>a mixt. of esters of C8-18 satd. fatty acids with glycerol and polyethylene glycol.</u> Gelucire 44/14 was melted by heating to 60.degree. and powd. N-benzoylstaurosporine was added to the molten material. The resulting mixt. was homogenized and filled into capsules for oral administration.				

11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:357113 CAPLUS

DN 125:19059

TI Intravenous solutions containing staurosporine derivatives

IN Weder, Hans Georg; Isele, Ute

PA Ciba-Geigy A.-G., Switz.

SO Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 711556	A1	19960515	EP 1995-810686	19951101
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9536616	A1	19960523	AU 1995-36616	19951102
	AU 9536617	A1	19960523	AU 1995-36617	19951102
	FI 9505311	A	19960510	FI 1995-5311	19951106
	FI 9505312	A	19960510	FI 1995-5312	19951106
	CA 2162341	AA	19960510	CA 1995-2162341	19951107
	CA 2162342	AA	19960510	CA 1995-2162342	19951107
	HU 74423	A2	19961230	HU 1995-3199	19951107
	US 5658898	A	19970819	US 1995-553126	19951107
	HU 78026	A2	19990528	HU 1995-3198	19951107
	ZA 9509457	A	19960509	ZA 1995-9457	19951108
	NO 9504485	A	19960510	NO 1995-4485	19951108
	NO 9504486	A	19960510	NO 1995-4486	19951108
	ZA 9509458	A	19960620	ZA 1995-9458	19951108
	JP 08208486	A2	19960813	JP 1995-289508	19951108
	JP 08208522	A2	19960813	JP 1995-289511	19951108
PRAI	CH 1994-3375		19941109		
	CH 1995-595		19950302		

OS MARPAT 125:19059

AB Poorly sol. staurosporine derivs., esp. N-benzoylstaurosporine, are formulated with a combination of phospholipids, triglycerides, and partial fatty esters of polyoxyethylene-sorbitan as solubilizers for i.v. administration. Staurosporine derivs. are useful as neoplasm and inflammation inhibitors, antibiotics, antiarteriosclerotics, etc. Thus, an oily mixt. of N-benzoylstaurosporine 9.0, Miglyol 812 100.0, and Tween 80 150.0 g was homogenized with an aq. liposome dispersion contg. 50.0 g Lipoid S 100 and the nanoemulsion was sterilized by filtration for i.v. injection.

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:300081 CAPLUS
 DN 122:64402
 TI Galenic-formulations of-macrolides such as rapamycin
 IN Fricker, Gerd; Haeberlin, Barbara; Meinzer, Armin; Vonderscher, Jacky
 PA Sandoz-Patent-G.m.b.H., Germany
 SO Ger. Offen., 10 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4418115	A1	19941201	DE 1994-4418115	19940524
	CH 686761	A	19960628	CH 1994-1564	19940520
	GB 2278780	A1	19941214	GB 1994-10252	19940523
	GB 2278780	B2	19981014		
	GB 2315216	A1	19980128	GB 1997-22958	19940523
	GB 2315216	B2	19981014		
	CA 2124259	AA	19941128	CA 1994-2124259	19940525
	AT 9401065	A	20010515	AT 1994-1065	19940525
	AT 408521	B	20011227		
	FR 2705566	A1	19941202	FR 1994-6515	19940526
	FR 2705566	B1	19960405		
	JP 07138161	A2	19950530	JP 1994-112554	19940526
	JP 3121203	B2	20001225		
	BE 1008329	A3	19960402	BE 1994-531	19940526
	ES 2098180	A1	19970416	ES 1994-1166	19940526
	ES 2098180	B1	19980701		
	JP 11315022	A2	19991116	JP 1999-60128	19940526
	US 5932243	A	19990803	US 1997-916243	19970822
	AT 9701722	A	20011015	AT 1997-1722	19971013
	AT 409082	B	20020527		
	HK 1011278	A1	20000512	HK 1998-111891	19981110
	HK 1022258	A1	20010622	HK 2000-100136	19981110
	US 6565859	B1	20030520	US 2000-532999	20000322
	AT 408520	B	20011227	AT 2000-1228	20000714
	US 2003166517	A1	20030904	US 2003-387147	20030312
PRAI	GB 1993-10974	A	19930527		
	GB 1993-20463	A	19931005		
	GB 1994-10252	A3	19940523		
	AT 1994-1065	A	19940525		
	US 1994-248993	B1	19940525		
	JP 1994-112554	A3	19940526		
	US 1997-916243	A1	19970822		
	US 1999-324489	B1	19990602		
	US 2000-532999	A1	20000322		
AB	The title formulations comprise emulsion or microemulsion preconcs. in which the lipophilic phase, surfactant, and hydrophilic phase constitute 10-855, 5-80, and 10-50 wt.% of the carrier, resp. These formulations are well absorbed when administered orally. Thus, a mixt. of rapamycin 20.0, EtOH 75.0, 1,2-propylene glycol 81.0, refined grain oil 121.5, and Cremophor RH40 202.5 mg was placed in a hard gelatin capsule.				

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:672544 CAPLUS
 DN 125:309030
 TI Nanosuspensions of N-benzoylstaurosporine for intravenous application
 IN Weder, Hans Georg; Van Hoogevest, Peter
 PA Ciba-Geigy A.-G., Switz.
 SO Eur. Pat. Appl., 8 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 733358	A2	19960925	EP 1996-810150	19960312
	EP 733358	A3	19980520		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9648094	A1	19961003	AU 1996-48094	19960315
	AU 9648095	A1	19961003	AU 1996-48095	19960315
	CA 2172110	AA	19960922	CA 1996-2172110	19960319
	CA 2172111	AA	19960922	CA 1996-2172111	19960319
	JP 08268915	A2	19961015	JP 1996-63092	19960319
	JP 08268893	A2	19961015	JP 1996-63194	19960319
	NO 9601136	A	19960923	NO 1996-1136	19960320
	NO 9601137	A	19960923	NO 1996-1137	19960320
	ZA 9602248	A	19960923	ZA 1996-2248	19960320
	ZA 9602249	A	19960923	ZA 1996-2249	19960320
	US 5726164	A	19980310	US 1996-619068	19960320
PRAI	CH 1995-804		19950321		

AB The title poorly water-sol. staurosporine deriv. (I), a protein kinase C inhibitor and antitumor agent, is solubilized for i.v. administration by dispersion with a polyoxyethylene-polyoxypropylene block copolymer, soybean lecithin or other phospholipid, EtOH, and H2O. The resulting nanosuspension (particle size 5-20 nm) shows excellent homogeneity and storage stability. Thus, an aq. infusion soln. contained glucose 5, I 0.12, Lutrol F68 0.60, soybean lecithin 0.12, glycerin 1.80, 70% sorbitol soln. 0.88, and 96% EtOH 2.10%.

AN 1998:542978 CAPLUS
 DN 129:153262
 TI Oil-free pharmaceutical compositions containing cyclosporin A
 IN Meinzer, Armin; Haeberlin, Barbara
 PA Novartis A.G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9833512	A1	19980806	WO 1998-EP453	19980128
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	GB 2355195	A1	20010418	GB 2000-24188	19970207
	GB 2355195	B2	20010912		
	AU 9862141	A1	19980825	AU 1998-62141	19980128
	AU 737053	B2	20010809		
	GB 2335854	A1	19991006	GB 1999-17521	19980128
	GB 2335854	B2	20010425		
	DE 19882037	T	19991216	DE 1998-19882037	19980128
	BR 9807528	A	20000314	BR 1998-7528	19980128
	EP 988046	A1	20000329	EP 1998-904156	19980128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
	JP 2000516256	T2	20001205	JP 1998-532524	19980128
	NZ 336900	A	20010629	NZ 1998-336900	19980128
	DE 29824679	U1	20020502	DE 1998-29824679	19980128
	EP 1331002	A2	20030730	EP 2003-7982	19980128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
	RU 2211047	C2	20030827	RU 1999-118508	19980128
	US 6475519	B1	20021105	US 1999-284391	19990413
	MX 9906916	A	20000131	MX 1999-6916	19990726
	AU 762247	B2	20030619	AU 2001-53938	20010620
	US 2002119190	A1	20020829	US 2001-992584	20011106
PRAI	GB 1997-1881	A	19970130		
	GB 1997-2594	A	19970207		
	AU 1998-62141	A3	19980128		
	EP 1998-904156	A3	19980128		
	WO 1998-EP453	W	19980128		
	US 1999-284391	A1	19990413		
AB	A hard gelatin capsule contains a pharmaceutical compn. comprising cyclosporin A mixed with a surfactant of HLB value .gtoreq.10, substantially free of any oil, and optionally a thickener. When a hydrophilic phase is present, it is a PEG and/or a lower alkanol, provided that any lower alkanol is present at <12% of the total wt. of the compn. (not counting the hard gelatin capsule). Thus, hard gelatin capsules each contained cyclosporin A 50 mg, Cremophor Recombinant Human (surfactant) 300 mg, and 1,2-propylene glycol 8 wt.%.				
RE.CNT	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD			
		ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L7 ANSWER 5 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:672543 CAPLUS
DOCUMENT NUMBER: 125:309029
TITLE: Pharmaceutical base for the formulation of
nanosuspensions
INVENTOR(S): Weder, Hans Georg; Van Hoogevest, Peter
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.; Vesifact Ag
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733372	A2	19960925	EP 1996-810151	19960312
EP 733372	A3	19980520		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9648094	A1	19961003	AU 1996-48094	19960315
AU 9648095	A1	19961003	AU 1996-48095	19960315
CA 2172110	AA	19960922	CA 1996-2172110	19960319
CA 2172111	AA	19960922	CA 1996-2172111	19960319
JP 08268915	A2	19961015	JP 1996-63092	19960319
JP 08268893	A2	19961015	JP 1996-63194	19960319
NO 9601136	A	19960923	NO 1996-1136	19960320
NO 9601137	A	19960923	NO 1996-1137	19960320
ZA 9602248	A	19960923	ZA 1996-2248	19960320
ZA 9602249	A	19960923	ZA 1996-2249	19960320
US 5726164	A	19980310	US 1996-619068	19960320
PRIORITY APPLN. INFO.:			CH 1995-804	19950321

AB A base for formulation of pharmaceutical nanosuspensions of an active agent (e.g. N-benzoylstaurosporine, a poorly water-sol. protein kinase C inhibitor and antitumor agent) contains a polyoxyethylene-polyoxypropylene block copolymer, soybean lecithin or other phospholipid, EtOH, and H₂O. The resulting nanosuspension (particle size 5-20 nm) shows excellent homogeneity and storage stability. Thus, an aq. infusion soln. contained glucose 5, N-benzoylstaurosporine 0.12, Lutrol F68 0.60, soybean lecithin 0.12, glycerin 1.80, 70% sorbitol soln. 0.88, and 96% EtOH 2.10%.

L7 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:672544 CAPLUS
DOCUMENT NUMBER: 125:309030
TITLE: Nanosuspensions of N-benzoylstaurosporine
for intravenous application
INVENTOR(S): Weder, Hans Georg; Van Hoogevest, Peter
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733358	A2	19960925	EP 1996-810150	19960312
EP 733358	A3	19980520		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9648094	A1	19961003	AU 1996-48094	19960315
AU 9648095	A1	19961003	AU 1996-48095	19960315
CA 2172110	AA	19960922	CA 1996-2172110	19960319
CA 2172111	AA	19960922	CA 1996-2172111	19960319
JP 08268915	A2	19961015	JP 1996-63092	19960319
JP 08268893	A2	19961015	JP 1996-63194	19960319
NO 9601136	A	19960923	NO 1996-1136	19960320
NO 9601137	A	19960923	NO 1996-1137	19960320
ZA 9602248	A	19960923	ZA 1996-2248	19960320
ZA 9602249	A	19960923	ZA 1996-2249	19960320
US 5726164	A	19980310	US 1996-619068	19960320
PRIORITY APPLN. INFO.:			CH 1995-804	19950321

AB The title poorly water-sol. staurosporine deriv. (I), a protein kinase C inhibitor and antitumor agent, is solubilized for i.v. administration by dispersion with a **polyoxyethylene**-polyoxypropylene block **copolymer**, soybean lecithin or other phospholipid, EtOH, and H₂O. The resulting nanosuspension (particle size 5-20 nm) shows excellent homogeneity and storage stability. Thus, an aq. infusion soln. contained glucose 5, I 0.12, Lutrol F68 0.60, soybean lecithin 0.12, glycerin 1.80, 70% sorbitol soln. 0.88, and 96% EtOH 2.10%.

L7 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:592531 CAPLUS
DOCUMENT NUMBER: 133:183006
TITLE: Spontaneously dispersible N-
benzoylstaurosporine compositions
INVENTOR(S): Matthews, Graham Paul; Haberlin, Barbara
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen
Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048571	A1	20000824	WO 2000-EP1196	20000214
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000008228	A	20011030	BR 2000-8228	20000214
EP 1152750	A1	20011114	EP 2000-909165	20000214
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002537242	T2	20021105	JP 2000-599363	20000214
NO 2001003964	A	20011015	NO 2001-3964	20010815
US 2002061873	A1	20020523	US 2001-930335	20010815
PRIORITY APPLN. INFO.:			GB 1999-3547 A 19990216	
			WO 2000-EP1196 W 20000214	
AB	Spontaneously dispersible N- benzoylstaurosporine compns. are described, for oral administration, having high bioavailability levels and reduced variability of bioavailability levels of N- benzoylstaurosporine , as well as their prepn. and use in treatment. Thus, a formulation contained Cremophor RH-40 42.750, PEG-400 25.65, ETOH 9.500, corn oil glycerides 17.005, tocopherol 0.095, and N- benzoylstaurosporine 5.000%.			
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L7 ANSWER 1 OF 40 USPATFULL on STN

ACCESSION NUMBER: 2002:119885 USPATFULL
TITLE: Spontaneously dispersible N-benzoyl staurosporine compositions
INVENTOR(S): Matthews, Graham Paul, Horsham, UNITED KINGDOM
Haeberlin, Barbara, Munchenstein, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061873	A1	20020523
APPLICATION INFO.:	US 2001-930335	A1	20010815 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-EP1196, filed on 14 Feb 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-3547	19990216
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	849	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:754189 CAPLUS
DOCUMENT NUMBER: 137:268463
TITLE: Pharmaceutical compositions containing **surfactants** and polymers
INVENTOR(S): Ebner, Andreas; Galli, Bruno
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076432	A2	20021003	WO 2002-EP3387	20020326
WO 2002076432	A3	20021212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
DE 10117049	A1	20021017	DE 2001-10117049	20010405
PRIORITY APPLN. INFO.:			DE 2001-10114869 A	20010326

AB A Solid compn. comprising (a) an anionic **surfactant** in combination with a water-sol. and basic polymer, or (b) a cationic **surfactant** in combination with a water-sol. and acidic polymer, and (c) at least 1 poorly water-sol. drug, and solid or liq. dosage forms, esp. tablets, coated tablets, capsules or suppositories or aq. solns. comprising the solid compn. The **surfactant**/polymer system is sol. in water and solubilizes the active ingredient so that good bioavailability with therapeutical quantities may be attained. Aq. solns. are suitable for nasal, parenteral or ophthalmic treatments. PVP-K30 (10 mg/mL), 10 mg/mL sodium dodecyl sulfate and an excess of PKC-412 are added at 25.degree. to water or pH 6.8 phosphate buffer. The mixt. is stirred for 24 h, whereby the polymer and the **surfactant** are completely dissolved, after which the mixt. is filtered. A clear soln. is obtained which contains 4.1 mg/mL of PKC-412. The soln. also remains unchanged after storage for 1 yr.

L7 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2000:592531 CAPLUS
 DOCUMENT NUMBER: 133:183006
 TITLE: Spontaneously dispersible N-
benzoylstauroporine compositions
 INVENTOR(S): Matthews, Graham Paul; Haberlin, Barbara
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen
 Verwaltungsgesellschaft m.b.H.
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048571	A1	20000824	WO 2000-EP1196	20000214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000008228	A	20011030	BR 2000-8228	20000214
EP 1152750	A1	20011114	EP 2000-909165	20000214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537242	T2	20021105	JP 2000-599363	20000214
NO 2001003964	A	20011015	NO 2001-3964	20010815
US 2002061873	A1	20020523	US 2001-930335	20010815
PRIORITY APPLN. INFO.: GB 1999-3547 A 19990216 WO 2000-EP1196 W 20000214				

AB Spontaneously dispersible N-**benzoylstauroporine** compns. are described, for oral administration, having high bioavailability levels and reduced variability of bioavailability levels of N-**benzoylstauroporine**, as well as their prepn. and use in treatment. Thus, a formulation contained Cremophor RH-40 42.750, PEG-400 25.65, EtOH 9.500, corn oil glycerides 17.005, tocopherol 0.095, and N-**benzoylstauroporine** 5.000%.

RE
 (1) Ciba-Geigy Ag; EP 0657164 A 1995 CAPLUS
 (2) Ciba-Geigy Ag; EP 0711556 A 1996 CAPLUS
 (3) Ciba-Geigy Ag; EP 0733358 A 1996 CAPLUS
 (4) Novartis Ag; WO 9833512 A 1998 CAPLUS
 (5) Sandoz-Patent-GmbH; DE 4418115 A 1994 CAPLUS

L7 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:357113 CAPLUS
DOCUMENT NUMBER: 125:19059
TITLE: Intravenous solutions containing staurosporine derivatives
INVENTOR(S): Weder, Hans Georg; Isele, Ute
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 711556	A1	19960515	EP 1995-810686	19951101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9536616	A1	19960523	AU 1995-36616	19951102
AU 9536617	A1	19960523	AU 1995-36617	19951102
FI 9505311	A	19960510	FI 1995-5311	19951106
FI 9505312	A	19960510	FI 1995-5312	19951106
CA 2162341	AA	19960510	CA 1995-2162341	19951107
CA 2162342	AA	19960510	CA 1995-2162342	19951107
HU 74423	A2	19961230	HU 1995-3199	19951107
US 5658898	A	19970819	US 1995-553126	19951107
HU 78026	A2	19990528	HU 1995-3198	19951107
ZA 9509457	A	19960509	ZA 1995-9457	19951108
NO 9504485	A	19960510	NO 1995-4485	19951108
NO 9504486	A	19960510	NO 1995-4486	19951108
ZA 9509458	A	19960620	ZA 1995-9458	19951108
JP 08208486	A2	19960813	JP 1995-289508	19951108
JP 08208522	A2	19960813	JP 1995-289511	19951108
PRIORITY APPLN. INFO.:			CH 1994-3375	19941109
			CH 1995-595	19950302

OTHER SOURCE(S): MARPAT 125:19059

AB Poorly sol. staurosporine derivs., esp. N-benzoylstaurosporine, are formulated with a combination of phospholipids, triglycerides, and partial fatty esters of polyoxyethylene-sorbitan as solubilizers for i.v. administration. Staurosporine derivs. are useful as neoplasm and inflammation inhibitors, antibiotics, antiarteriosclerotics, etc. Thus, an oily mixt. of N-benzoylstaurosporine 9.0, Miglyol 812 100.0, and Tween 80 150.0 g was homogenized with an aq. liposome dispersion contg. 50.0 g Lipoid S 100 and the nanoemulsion was sterilized by filtration for i.v. injection.

7 ANSWER 6 OF 40 USPATFULL on STN

ACCESSION NUMBER: 1998:25218 USPATFULL
TITLE: Nanosuspensions for intravenous administration
INVENTOR(S): Weder, Hans Georg, Ruschlikon, Switzerland
van Hoogevest, Peter, Riehen, Switzerland
PATENT ASSIGNEE(S): Novartis Corporation, Summit, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5726164		19980310
APPLICATION INFO.:	US 1996-619068		19960320 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1995-804	19950321
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ivy, C. Warren	
ASSISTANT EXAMINER:	Mach, D. Margaret M.	
LEGAL REPRESENTATIVE:	Mathias, Marla J., Ferraro, Gregory D.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	576	



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical composition for the intravenous administration of the sparingly soluble staurosporin derivative N-benzoyl-staurosporin. The composition comprises the following preferred components:

- a) the therapeutic agent N-benzoyl-staurosporin;
- b) a polyoxyethylene/polyoxypropylene block copolymer;
- c) ethanol and water as carrier liquids; and
- d) purified lecithin from soybeans and
- e) as water-soluble excipients glycerol and sorbitol.

ACCESSION NUMBER: 1998:709050 CAPLUS
 DOCUMENT NUMBER: 129:343416
 TITLE: Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and their use as sodium channel blockers
 INVENTOR(S): Wang, Yan; Cai, Sui Xiong; Lan, Nancy C.; Keana, John F. W.; Ilyin, Victor I.; Weber, Eckard
 PATENT ASSIGNEE(S): Cocensys, Inc., USA
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847869	A1	19981029	WO 1998-US8004	19980422
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9874676	A1	19981113	AU 1998-74676	19980422
AU 738197	B2	20010913		
EP 986540	A1	20000322	EP 1998-922043	19980422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9809288	A	20010807	BR 1998-9288	19980422
JP 2001526648	T2	20011218	JP 1998-546269	19980422
NO 9905094	A	19991220	NO 1999-5094	19991019
US 2002061886	A1	20020523	US 2001-3249	20011206
PRIORITY APPLN. INFO.:				
			US 1997-44530P	P 19970422
			US 1997-62649P	P 19971022
			WO 1998-US8004	W 19980422
			US 1999-421403	A3 19991021
OTHER SOURCE(S): MARPAT 129:343416				
GI				



AB The invention relates to carbocyclic and heterocyclic substituted

semicarbazones and thiosemicarbazones I and their pharmaceutically acceptable salts or prodrugs [wherein Y = O or S; R1, R21, R22 and R23 = H, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, or carboxyalkyl; or NR22R23 forms a heterocycle; A1, A2 = (un)substituted aryl, heteroaryl, satd. or partially unsatd. carbocycle, or satd. or partially unsatd. heterocycle; X = O, S, NR24, CR25R26, CO, NR24CO, CONR24, SO, SO2, or a covalent bond; R24, R25, and R26 = H, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, or carboxyalkyl]. The invention is also directed to the use of such compds. for treatment of neuronal damage following global and focal ischemia, for treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity, for treatment, prevention, or amelioration of pain, as anticonvulsants, as anti-manic-depressants, as local anesthetics, as antiarrhythmics, and for the treatment or prevention of diabetic neuropathy and urinary incontinence. Approx. 180 such compds. were prepd., claimed in use, and/or claimed per se. For instance, 4-FC6H4CHO was etherified with 5-chloro-2-pyridinol using K2CO3 in AcNMe2, and the resultant 4-(4-chloro-2-pyridinyloxy)benzaldehyde in EtOH reacted with semicarbazide-HCl and NaOAc in H2O to give title compd. II. Exemplary biol. data for several compds. is given, and includes Na+ channel blocking, analgesic, and anticonvulsant activities. For instance, 4-(4-fluorophenoxy)benzaldehyde semicarbazone inhibited Na+ currents in rat hippocampal neurons (site 2) with IC50 of 22 .mu.M, vs. 29.9 .mu.M for lidocaine and >100 .mu.M for tetrodotoxin, although the reverse order was obsd. at site 1.

IT **181144-66-1**, 4-(4-Fluorophenoxy)benzaldehyde semicarbazone
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (pharmaceutical use; prepn. of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers)

2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:357113 CAPLUS
DOCUMENT NUMBER: 125:19059
TITLE: Intravenous solutions containing staurosporine derivatives
INVENTOR(S): Weder, Hans Georg; Isele, Ute
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 711556	A1	19960515	EP 1995-810686	19951101 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9536616	A1	19960523	AU 1995-36616	19951102
AU 9536617	A1	19960523	AU 1995-36617	19951102
FI 9505311	A	19960510	FI 1995-5311	19951106
FI 9505312	A	19960510	FI 1995-5312	19951106
CA 2162341	AA	19960510	CA 1995-2162341	19951107
CA 2162342	AA	19960510	CA 1995-2162342	19951107
HU 74423	A2	19961230	HU 1995-3199	19951107
US 5658898	A	19970819	US 1995-553126	19951107
HU 78026	A2	19990528	HU 1995-3198	19951107
ZA 9509457	A	19960509	ZA 1995-9457	19951108
NO 9504485	A	19960510	NO 1995-4485	19951108
NO 9504486	A	19960510	NO 1995-4486	19951108
ZA 9509458	A	19960620	ZA 1995-9458	19951108
JP 08208486	A2	19960813	JP 1995-289508	19951108
JP 08208522	A2	19960813	JP 1995-289511	19951108
PRIORITY APPLN. INFO.:			CH 1994-3375	19941109
			CH 1995-595	19950302

OTHER SOURCE(S): MARPAT 125:19059

AB Poorly sol. staurosporine derivs., esp. N-benzoylstaurosporine, are formulated with a combination of phospholipids, triglycerides, and partial fatty esters of polyoxyethylene-sorbitan as solubilizers for i.v. administration. Staurosporine derivs. are useful as neoplasm and inflammation inhibitors, antibiotics, antiarteriosclerotics, etc. Thus, an oily mixt. of N-benzoylstaurosporine 9.0, Miglyol 812 100.0, and Tween 80 150.0 g was homogenized with an aq. liposome dispersion contg. 50.0 g Lipoid S 100 and the nanoemulsion was sterilized by filtration for i.v. injection.

ACCESSION NUMBER: 1996:672544 CAPLUS
 DOCUMENT NUMBER: 125:309030
 TITLE: Nanosuspensions of N-benzoylstaurosporine for intravenous application
 INVENTOR(S): Weder, Hans Georg; Van Hoogevest, Peter
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 8 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733358	A2	19960925	EP 1996-810150	19960312 <--
EP 733358	A3	19980520		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9648094	A1	19961003	AU 1996-48094	19960315
AU 9648095	A1	19961003	AU 1996-48095	19960315
CA 2172110	AA	19960922	CA 1996-2172110	19960319
CA 2172111	AA	19960922	CA 1996-2172111	19960319
JP 08268915	A2	19961015	JP 1996-63092	19960319
JP 08268893	A2	19961015	JP 1996-63194	19960319
NO 9601136	A	19960923	NO 1996-1136	19960320
NO 9601137	A	19960923	NO 1996-1137	19960320
ZA 9602248	A	19960923	ZA 1996-2248	19960320
ZA 9602249	A	19960923	ZA 1996-2249	19960320
US 5726164	A	19980310	US 1996-619068	19960320
PRIORITY APPLN. INFO.:			CH 1995-804	19950321

AB The title poorly water-sol. staurosporine deriv. (I), a protein kinase C inhibitor and antitumor agent, is solubilized for i.v. administration by dispersion with a polyoxyethylene-polyoxypropylene block copolymer, soybean lecithin or other phospholipid, EtOH, and H₂O. The resulting nanosuspension (particle size 5-20 nm) shows excellent homogeneity and storage stability. Thus, an aq. infusion soln. contained glucose 5, I 0.12, Lutrol F68 0.60, soybean lecithin 0.12, glycerin 1.80, 70% sorbitol soln. 0.88, and 96% EtOH 2.10%.

6 ANSWER 1 OF 9 USPATFULL

ACCESSION NUMBER: 2002:119885 USPATFULL
 TITLE: Spontaneously dispersible N-benzoyl staurosporine compositions
 INVENTOR(S): Matthews, Graham Paul, Horsham, UNITED KINGDOM
 Haeberlin, Barbara, Munchenstein, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061873	A1	20020523
APPLICATION INFO.:	US 2001-930335	A1	20010815 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-EP1196, filed on 14 Feb 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-3547	19990216
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	849	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 120685-11-2, N-Benzoyl staurosporine
 (spontaneously dispersible benzoylstaurosporine compns.)

L6 ANSWER 2 OF 9 USPATFULL

ACCESSION NUMBER: 2001:163016 USPATFULL
 TITLE: Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
 INVENTOR(S): Weiss, Samuel, Calgary, Canada
 Reynolds, Brent, Calgary, Canada
 Hammang, Joseph P., Barrington, RI, United States
 Baetge, E. Edward, Barrington, RI, United States
 PATENT ASSIGNEE(S): Neurospheres Holdings, Ltd., Alberta, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6294346	B1	20010925
APPLICATION INFO.:	US 1995-484406		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned, said Ser. No. US 484406 And Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned, said		

Ser. No. US 484406 And Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned Continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 726812 , said Ser. No. US 338730 Continuation-in-part of Ser. No. US 726812 , said Ser. No. US 311099 Continuation-in-part of Ser. No. US 726812 , said Ser. No. US 270412 Continuation-in-part of Ser. No. US 726812

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary L.
ASSISTANT EXAMINER: Hayes, Robert C.
LEGAL REPRESENTATIVE: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,
Elrifi, Esq., Ivor R.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 4153

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A culture method for determining the effect of a biological agent on multipotent neural stem cell progeny is provided. In the presence of growth factors, multipotent neural stem cells are induced to proliferate in culture. The multipotent neural stem cells may be obtained from normal neural tissue or from a donor afflicted with a disease such as Alzheimer's Disease, Parkinson's Disease or Down's Syndrome. At various stages in the differentiation process of the multipotent neural stem cell progeny, the effects of a biological agent, such as a virus, protein, peptide, amino acid, lipid, carbohydrate, nucleic acid or a drug or pro-drug on cell activity are determined. Additionally, a method of screening the effects of biological agents on a clonal population of neural cells is provided. The technology provides an efficient method for the generation of large numbers of pre- and post-natal neural cells under controlled, defined conditions. The disclosed cultures provide an optimal source of normal and diseased neural cells at various developmental stages, which can be screened for potential side effects in addition to testing the action and efficacy of different biological agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 120685-11-2, CGP-41251

(use of multipotent neural stem cells and progeny for screening of drugs and other biol. agents)

L6 ANSWER 3 OF 9 USPATFULL

ACCESSION NUMBER: 2000:70818 USPATFULL

TITLE: In vivo genetic modification of growth factor-responsive neural precursor cells

INVENTOR(S): Weiss, Samuel, Alberta, Canada
Reynolds, Brent, Alberta, Canada

Hammang, Joseph P., Barrington, RI, United States

Baetge, E. Edward, Barrington, RI, United States

PATENT ASSIGNEE(S): NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6071889		20000606
APPLICATION INFO.:	US 1995-479795		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned And a continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned And a continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned And a continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned And a continuation-in-part of Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned And a continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned which is a continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned which is a continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned which is a continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Crouch, Deborah
ASSISTANT EXAMINER: Baker, Anne-Marie
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 4261

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for administering genetic material to dividing neural precursor cell populations in vivo are provided. The genetic material may comprise useful genes for neurotransmitters, growth factors, growth factor receptors, and the like. The genetic material is administered to the brain with one or more growth factors. The growth factors induce proliferation of neural precursor cells, thereby facilitating the incorporation of the genetic material into the cell progeny.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 120685-11-2, CGP-41251
(in vivo genetic modification of growth factor-responsive neural precursor cells)

L6 ANSWER 4 OF 9 USPATFULL

ACCESSION NUMBER: 1998:131714 USPATFULL
TITLE: Carbazole derivatives as agents against multi-drug resistance
INVENTOR(S): Regenass, Urs, Ettingen, Switzerland
Caravatti, Giorgio, Allschwil, Switzerland
Wacker, Oskar, Basel, Switzerland
PATENT ASSIGNEE(S): Novartis Corp., Summit, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5827846		19981027
	WO 9532974		19951207
APPLICATION INFO.:	US 1996-750155		19961127 (8)
	WO 1995-EP1909		19950519
			19961127 PCT 371 date
			19961127 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1994-1716	19940601
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Richter, Johann	
ASSISTANT EXAMINER:	Stockton, Laura L.	
LEGAL REPRESENTATIVE:	Borovian, Joseph J.	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1322	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The utility of known and novel staurosporin derivatives of formula I ##STR1## wherein R.sub.1 is formyl, an aliphatic hydrocarbon radical having up to 29 carbon atoms that is unsubstituted or substituted by aryl, or is an aryl radical,

R.sub.2 is hydrogen, C.sub.1 -C.sub.5 alkyl, benzoyl, lower alkanoyl or .alpha.-aminoacyl having a free or protected amino group, and

R.sub.3 is hydrogen, hydroxy, lower alkoxy or oxo,

or wherein

R.sub.1 is methoxycarbonylmethyl,

R.sub.2 is benzoyl, and

R.sub.3 is hydrogen,

for avoiding or removing multi-drug resistance to anti-tumour agents, such as vinblastine or adriamycin, is described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 120685-11-2
(prepn. of staurosporin derivs. as agents against multi-drug resistance)

L6 ANSWER 5 OF 9 USPATFULL

ACCESSION NUMBER: 1998:45195 USPATFULL
 TITLE: Combination for treatment of proliferative diseases
 INVENTOR(S): Muller, Marcel, Allschwil, Switzerland
 Geiger, Thomas, Freiburg, Germany, Federal Republic of
 Altmann, Karl-Heinz, Reinach, Switzerland
 Fabbro, Dorian, Arlesheim, Switzerland
 Dean, Nicholas M., Encinitas, CA, United States
 Monia, Brett, Carlsbad, CA, United States
 Bennett, Clarence Frank, Carlsbad, CA, United States
 PATENT ASSIGNEE(S): Novartis Corporation, Summit, NJ, United States (U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5744460		19980428
APPLICATION INFO.:	US 1996-612775		19960307 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Robinson, Douglas W.		
ASSISTANT EXAMINER:	Nelson, Amy J.		
LEGAL REPRESENTATIVE:	Nowak, Henry P.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2910		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to combinations of PKC-targeted (especially PKC-.alpha.-targeted) deoxyribo- and ribo-oligonucleotides and derivatives thereof with other chemotherapeutic compounds, as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to such oligonucleotides or oligonucleotide derivatives, especially to to modulation of the activity of a regulatory protein. In particular, the invention relates to products or combinations comprising antisense oligonucleotides or oligonucleotide derivatives targeted to nucleic acids encoding human PKC and other (preferably standard) chemotherapeutics, either in fixed combination or for chronologically staggered or simultaneous administration, and the combined use of both classes of compounds, either in fixed combination or for chronologically staggered or simultaneous administration, for the treatment of proliferative diseases, especially tumor diseases, that can be treated by inhibition of PKC activity, that is, where the antisense oligonucleotides or oligonucleotide derivatives are targeted to nucleic acids encoding the regulatory protein PKC or active mutated derivatives thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **120685-11-2**, N-Benzoylstauroporine
 (combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases)

L6 ANSWER 6 OF 9 USPATFULL

ACCESSION NUMBER: 1998:36750 USPATFULL
 TITLE: Pharmaceutical compositions containing a staurosporine
 INVENTOR(S): Henry, Roy Lindsay Allen, Horsham, England
 Matthews, Graham Paul, Horsham, England
 PATENT ASSIGNEE(S): Novartis Corporation, Summit, NJ, United States (U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5736542		19980407
APPLICATION INFO.:	US 1994-343404		19941122 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-25395	19931211
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Spivack, Phyllis G.	
LEGAL REPRESENTATIVE:	Mathias, Marla J., Kaiser, Karen G.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	217	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An orally administrable pharmaceutical composition comprising a solution or dispersion of a staurosporine active ingredient in a solid saturated polyalkylene glycol glyceride, such as a mixture of esters of C.sub.8 -C.sub.18 saturated fatty acids with glycerol and polyethylene glycol, is disclosed that may be administered in capsules or as a dispersion in an aqueous medium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **120685-11-2**, N-Benzoylstaurosporine
(dispersions contg. staurosporine derivs. in satd. polyalkylene glycol glycerides)

=>

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:592531 CAPLUS
DOCUMENT NUMBER: 133:183006
TITLE: Spontaneously dispersible N-
benzoylstaurosporine compositions
INVENTOR(S): Matthews, Graham Paul; Haberlin, Barbara
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen
Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048571	A1	20000824	WO 2000-EP1196	20000214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000008228	A	20011030	BR 2000-8228	20000214
EP 1152750	A1	20011114	EP 2000-909165	20000214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001003964	A	20011015	NO 2001-3964	20010815
US 2002061873	A1	20020523	US 2001-930335	20010815
PRIORITY APPLN. INFO.: GB 1999-3547 A 19990216 WO 2000-EP1196 W 20000214				

AB Spontaneously dispersible N-**benzoylstaurosporine**
comps. are described, for oral administration, having high
bioavailability levels and reduced variability of bioavailability levels
of N-**benzoylstaurosporine**, as well as their prepn. and
use in treatment. Thus, a formulation contained Cremophor RH-40 42.750,
PEG-400 25.65, EtOH 9.500, corn oil glycerides 17.005, tocopherol 0.095,
and N-**benzoylstaurosporine** 5.000%.

IT 120685-11-2, N-Benzoyl staurosporine
RL: BPR (Biological process); BSU (Biological study, unclassified); THU
(Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(spontaneously dispersible benzoylstaurosporine comps.)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:708711 CAPLUS
DOCUMENT NUMBER: 123:93287
TITLE: Pharmaceutical compositions containing staurosporine
derivatives
INVENTOR(S): Henry, Roy Lindsay Allen; Matthews, Graham Paul
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 6 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 657164	A1	19950614	EP 1994-308954	19941202
EP 657164	B1	19991027		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5736542	A	19980407	US 1994-343404	19941122
AT 185970	E	19991115	AT 1994-308954	19941202
ES 2140512	T3	20000301	ES 1994-308954	19941202
IL 111872	A1	19980208	IL 1994-111872	19941205
AU 9480308	A1	19950622	AU 1994-80308	19941208
AU 692801	B2	19980618		
CA 2137764	AA	19950612	CA 1994-2137764	19941209
ZA 9409824	A	19950713	ZA 1994-9824	19941209
JP 07196512	A2	19950801	JP 1994-307534	19941212

PRIORITY APPLN. INFO.:

GB 1993-25395 A 19931211

AB An oral prepn. with an improved bioavailability, comprises a soln. or dispersion of a staurosporine active ingredient in a satd. polyalkylene **glycol** glyceride, such as a mixt. of esters of C8-18 satd. fatty acids with glycerol and polyethylene **glycol**. Gelucire 44/14 was melted by heating to 60.degree. and powd. N-**benzoylstauroporine** was added to the molten material. The resulting mixt. was homogenized and filled into capsules for oral administration.

IT **120685-11-2, N-Benzoylstauroporine**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dispersions contg. staurosporine derivs. in satd. polyalkylene **glycol** glycerides)

=>


CCESSION NUMBER: 1995:708711 CAPLUS
 DOCUMENT NUMBER: 123:93287
 TITLE: Pharmaceutical compositions containing staurosporine derivatives
 INVENTOR(S): Henry, Roy Lindsay Allen; Matthews, Graham Paul
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 6 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 657164	A1	19950614	EP 1994-308954	19941202
EP 657164	B1	19991027		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5736542	A	19980407	US 1994-343404	19941122
AT 185970	E	19991115	AT 1994-308954	19941202
ES 2140512	T3	20000301	ES 1994-308954	19941202
IL 111872	A1	19980208	IL 1994-111872	19941205
AU 9480308	A1	19950622	AU 1994-80308	19941208
AU 692801	B2	19980618		
CA 2137764	AA	19950612	CA 1994-2137764	19941209
ZA 9409824	A	19950713	ZA 1994-9824	19941209
JP 07196512	A2	19950801	JP 1994-307534	19941212
PRIORITY APPLN. INFO.:		GB 1993-25395	A	19931211

AB An oral prepn. with an improved bioavailability, comprises a soln. or dispersion of a staurosporine active ingredient in a satd. polyalkylene glycol glyceride, such as a mixt. of esters of C8-18 satd. fatty acids with glycerol and polyethylene glycol. Gelucire 44/14 was melted by heating to 60.degree. and powd. N-benzoylstaurosporine was added to the molten material. The resulting mixt. was homogenized and filled into capsules for oral administration.

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
 RN 120685-11-2 REGISTRY
 CN Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonine, benzamide deriv.
 CN Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, [9S-(9.alpha.,10.beta.,11.beta.,13.alpha.)]-
 OTHER NAMES:
 CN Benzoylstaurosporine
 CN CGP 41231
 CN CGP 41251
 CN Midostaurin
 CN **N-Benzoylstaurosporine**
 CN PKC 412
 FS STEREOSEARCH
 MF C35 H30 N4 O4
 SR CA
 LC STN Files: ADISINSIGHT, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, PHAR, PROMT, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

87 REFERENCES IN FILE CA (1967 TO DATE)
 87 REFERENCES IN FILE CAPLUS (1967 TO DATE)